HC Wainwright upgraded shares of Vor Biopharma (NASDAQ:VOR – Free Report) from a hold rating to a strong-buy rating in a research note issued to investors on Monday morning,Zacks.com reports.
Separately, Wall Street Zen cut Vor Biopharma to a “strong sell” rating in a research report on Saturday, June 28th.
View Our Latest Stock Report on Vor Biopharma
Vor Biopharma Trading Up 1.4%
About Vor Biopharma
Vor Biopharma, Inc, a clinical-stage company, develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It is developing VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies. The company’s VOR33 eHSCs lacks CD33, a protein that is expressed by AML blood cancer cells.
Recommended Stories
- Five stocks we like better than Vor Biopharma
- Investing in Construction Stocks
- Jefferies Raises Broadcom Price Target to $315: 19% Upside Ahead
- Why is the Ex-Dividend Date Significant to Investors?
- Whiplash for Investors: AeroVironment’s Confusing Stock Signals
- Trading Halts Explained
- The Ultimate Trump Bump: These Gov’t Backed Stocks Are Exploding
Receive News & Ratings for Vor Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vor Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
